OMCL

Omnicell, Inc. 2004 Annual Report (10-K) Summary

Business Context and Reporting Period

This report covers the fiscal year ended December 31, 2004. Omnicell, Inc. provides healthcare information technology solutions, specifically medication and supply dispensing automation systems, physician order management, and decision support tools for hospitals and healthcare facilities. The company operates primarily in the United States, with international sales handled through distributors. As of year-end, the company had installed over 32,000 systems at 1,566 healthcare facilities.

Key Financial Metrics

Note: Cash flow from operating activities was negative $4.3 million in 2004, compared to positive $7.7 million in 2003, primarily due to increased inventory and accounts receivable.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 21.4% year-over-year, driven by a 22.7% increase in product revenues and a 15.9% increase in service revenues.
• Profitability: Net income increased 45.1% to $10.6 million. Operating income improved significantly due to higher gross profit dollars, despite a slight compression in gross margin percentage (58.0% vs 58.4%).
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 21.7% to $52.1 million, reflecting a 19% increase in headcount to support sales and customer service growth.
• Balance Sheet: Inventory increased by $6.2 million to $14.6 million as the company built finished goods to support "turns" business (same-quarter installation). Accounts receivable increased by $7.4 million.
• Acquisitions: The company completed the acquisition of the SecureVault product line from Ariel Distributing in March 2004 for $0.6 million.

Guidance, Outlook, and Risks

Outlook and Strategy: Management plans to focus on running the business more efficiently in 2005, reducing reliance on "turns" business to improve predictability. The company expects service revenues to be slightly up in 2005. Headcount reductions are planned for the first quarter of 2005 to improve cost efficiency.

Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting related to the review of signed contracts prior to revenue recognition. A material contract was recognized in Q4 2004 but was not countersigned by Omnicell until January 3, 2005. Consequently, revenue was deferred to Q1 2005. The auditors issued an adverse opinion on the effectiveness of internal controls.

Accounting Changes: The company must adopt SFAS No. 123R (Share-Based Payment) by July 2005. Management estimates this could reduce earnings by up to $2.0 million per quarter in 2005.

Risks:

• Competition: Intense competition from larger entities like Pyxis (Cardinal Health), McKesson, and AmerisourceBergen.
• Revenue Recognition: Revenue is recognized only upon installation; delays in customer acceptance or construction can significantly impact quarterly results.
• Government Funding: $3.7 million in unsold receivables from U.S. government customers is subject to annual funding cycles.
• Legal Proceedings: A lawsuit by ePlus Government Inc. regarding a customer's failure to pay approximately $1.7 million is pending, though management expects a settlement without material payment.

Investor Verification Checklist

• Internal Control Remediation: Verify the specific steps taken in Q1 2005 to remediate the material weakness regarding contract countersigning and revenue recognition.
• Inventory Levels: Monitor inventory turnover and potential write-downs given the $6.2 million increase in inventory and the shift away from "turns" business.
• Impact of SFAS 123R: Assess the actual impact of the new stock-based compensation accounting standard on 2005 earnings guidance.
• Backlog Conversion: Track the conversion rate of the $46.9 million product backlog into recognized revenue to ensure installation timelines remain on schedule.
• Legal Settlement: Confirm the final resolution of the ePlus Government Inc. litigation.